Protein binding of cefazolin is saturable in vivo both between and within patients
about
Importance of relating efficacy measures to unbound drug concentrations for anti-infective agentsCombination prophylactic therapy with rifampin increases efficacy against an experimental Staphylococcus epidermidis subcutaneous implant-related infectionDetermination of Cefalothin and Cefazolin in Human Plasma, Urine and Peritoneal Dialysate by UHPLC-MS/MS: application to a pilot pharmacokinetic study in humans.Tissue pharmacokinetics of cefazolin in patients with lower limb infections.Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.Wound Penetration of Cefazolin, Ciprofloxacin, Piperacillin, Tazobactam, and Vancomycin During Negative Pressure Wound Therapy.Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass to optimize dosing regimens for children undergoing cardiac surgery.Cefazolin plasma protein binding and its covariates in neonates.A pilot and feasibility study of the plasma and tissue pharmacokinetics of cefazolin in an immature porcine model of pediatric cardiac surgery.Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy.Pharmacokinetics and protein binding of cefazolin in morbidly obese patients.Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine-induced colorectal cancer model rats.Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates.The complexity of minocycline serum protein binding.Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis.Effects of cardiopulmonary bypass on the disposition of cefazolin in patients undergoing cardiothoracic surgery
P2860
Q26827380-2563A412-2D1F-4718-8CBC-717D14AA6936Q33622963-69DBB8A5-71AB-4ACC-876F-F078A75EA65AQ35783893-F8703C57-2D7E-422B-98DC-121CC2DE6B94Q37263523-645E4886-0A85-42E8-8F4E-85740708832EQ38420688-E081A877-F43B-4377-B491-497F101EC15AQ38949043-A5A8C30D-6038-47F2-BF46-30A4E251301DQ39080543-AAF7F2A5-2A4D-43E8-9B5D-FB5FA901BDE7Q39579691-3E0D4D7D-C77F-412A-B06D-C1CBC6251EE8Q40998498-FADD8CC3-A201-4E70-95AA-F1ED43B719B4Q41967888-72E2B84F-1879-44CC-9BBB-354976B19350Q45236532-8A7E9AF7-C97B-4855-815E-A6EC315E5F8FQ46454725-E37F4F37-5694-4618-BB30-0EAD1ED315CDQ50691157-C4C315F6-7665-4F04-9987-59F6A23F769AQ51089968-949AEC40-005C-43C9-A6EE-0D85A8CE19E0Q54626808-C4DE1CA2-4CEE-47CA-BD13-A220743C48D5Q58611889-BC78E147-7FCD-4119-9CB2-3DFA2310BA14
P2860
Protein binding of cefazolin is saturable in vivo both between and within patients
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Protein binding of cefazolin is saturable in vivo both between and within patients
@ast
Protein binding of cefazolin is saturable in vivo both between and within patients
@en
type
label
Protein binding of cefazolin is saturable in vivo both between and within patients
@ast
Protein binding of cefazolin is saturable in vivo both between and within patients
@en
prefLabel
Protein binding of cefazolin is saturable in vivo both between and within patients
@ast
Protein binding of cefazolin is saturable in vivo both between and within patients
@en
P2093
P2860
P1476
Protein binding of cefazolin is saturable in vivo both between and within patients
@en
P2093
Carl M J Kirkpatrick
Evan J Begg
Jane W A Vella-Brincat
Kate Gallagher
Stephen T Chambers
P2860
P304
P356
10.1111/J.1365-2125.2006.02827.X
P407
P577
2007-01-12T00:00:00Z